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nese women should be determined with consideration for multiple CRFs in terms
of cost-effectiveness.
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RAISE QUALITY AND LOWER COSTS
Peabody J1, Strand V2, Chernoff D3, Ta H1
1QURE Healthcare, San Rafael, CA, USA, 2Stanford University, Stanford, CA, USA, 3Crescendo
Bioscience, South San Francisco, CA, USA
OBJECTIVES: To determine the quality and variability of care in rheumatoid arthri-
tis (RA). METHODS: We recruited 109 board-certified rheumatologists. Physicians
evaluated 3 common RA cases: A) mild disease activity, inadequately treated with
conventional disease modifying antirheumatic drugs (DMARDs); B) increasing dis-
ease activity, inadequately treated with conventional DMARDs; and C) stable dis-
ease activity, adequately treated with DMARDs, with a complicating co-morbidity.
Clinical performance and value (CPV) vignettes, a validated case-mix adjusted
measure of clinical practice, assessed variability and quality of care. Consented
physicians completed one online vignette for each case-type obtaining a history,
physical examination, ordering tests and determining treatments. Criteria for eval-
uating clinical decisions were based on ACR guidelines, published evidence and
expert panels. Vignette scores are reported as percentages of total criteria correct
overall and by domain, (e.g., treatment prescribed). RESULTS: The mean quality
score for all simulated cases (n327 cases) was 61.3%%. Mean scores for history
were 62.8%; physical examination: 55.8%; laboratory testing and imaging: 61.1%;
disease activity assessment: 52.6% and treatment: 66.9%. Ordering unnecessary
tests was most common: rheumatologists ordered 1.8 additional laboratory and 1
additional imaging test. Among the 3 case types, lowest quality and most clinical
variability occurred in the case with the co-morbidity (Case C), associated with
unnecessary testing and inappropriate use of biologic and/or combination
DMARDs. Variability was also found in Cases A and B: 3 of 10 and 2 of 10 rheuma-
tologists, respectively, used combination and/or biologic DMARDs unnecessarily.
CONCLUSIONS: Improving quality and lowering cost is a strategic focus of payers
and providers. Using CPV vignettes, we found a wide range of variation in RA
practice, which resulted in unnecessary testing, repetition of potentially expensive
imaging studies and varying use of DMARDs. This variability indicates there are
opportunities to improve quality of care and lower costs.
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OBJECTIVES: To appraise existing economic evaluations of epidural steroid injec-
tions (ESIs) for lumbar spinal stenosis and to estimate Medicare-based reimbursed
amounts. METHODS: We searched PubMed through June 2011 for low back pain,
spinal stenosis or sciatica, and ESI and included observational studies with cost
outcomes. We performed a supplementary descriptive analysis of Medicare reim-
bursed amounts associated with ESI performed at a single institution in 2010.
RESULTS: Our literature search indicated that rates of lumbar ESI increased 271%
from 1994 to 2001 in Medicare beneficiaries 65 years of age with professional
charges per injection nearly doubling ($115 to $227) during this time period. A
second study found the rate of lumbar epidurals was 67% higher in 2006 versus
2002 in Medicare beneficiaries of any age, and allowed charges of all spine epidural
increased from $336 to $395. Our single-institution estimation sample included 279
patients receiving one (n179), two (N93), three (N30), or four (N2) ESIs. We
estimated mean total Medicare reimbursement per outpatient ESI episode proce-
dure to be $635 in 2010 (technical reimbursement and estimated professional pay-
ment). The associated reimbursement estimates were $1239 and $1834 for those
receiving 2 and 3 ESI episodes, respectively. CONCLUSIONS: There are few studies
investigating the economic impact of ESI procedures for lumbar spinal stenosis in
the elderly, or providing estimates of technical and professional reimbursement
amounts. Our single-institution estimate suggests thatMedicare-based reimburse-
ment is greater than $600 per ESI (technical and professional). More information on
utilization, costs, and cost-effectiveness of ESI in treating lumbar spinal stenosis
are needed.
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OBJECTIVES: To develop and implement patient-reported resource use question-
naires for assessing utilization and costs in elderly patients with lumbar spinal
stenosis (SS), as part of an epidural steroid injection randomized clinical trial (RCT)
in multiple integrated health systems. METHODS: We developed patient-com-
pleted diaries for a RCT in an elderly populationwith SS to capturemedication use,
time, and costs incurred by patients. Diary sections included: prescription opioid
medications, non-opioid analgesics and over-the-counter (OTC) products, thera-
peutic services, time spent for SS care, and products purchased for back pain. We
summarized demographics and commonly-reported opioid medications for cur-
rently-enrolled subjects. RESULTS:We implemented resource use diaries in a RCT
during baseline to week 3, weeks 4-6, weeks 24-26, and weeks 50-52. Overall, the
diaries capture 12 weeks of data, distributed at key time points, during 12 months.
The prescription opioid section and OTC section collect dose and daily medication
use intensity. Later sections capture weekly visits, time, and purchases for back
pain. We integrated the patient questionnaires into our overall electronic data
management system, including prompts for sites to send participants diaries, col-
lect diaries and enter the data on our RedCap™ electronic data capture system. To
date, 100 RCT participants completed baseline diaries. The mean age was 69.6
years, 59% were females, and approximately 29% were from minority groups. The
most commonly reported opioid medications were hydrocodone-acetaminophen
and acetaminophen-codeine.CONCLUSIONS: It is important to capture the patient
perspective in RCTs, particularly those with complex interactions among pain,
functioning, medication use and economic endpoints. Electronic medical records
are powerful tools to assess clinical and economic resource use, but still have
limitations on collecting what patients spend and do to manage their pain condi-
tion. Logistical challenges and patient burden of completing questionnaires must
be weighed against a more comprehensive economic evaluation andmanagement
of a high-priority condition.
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OBJECTIVES: To calculate expected mean annual golimumab costs based on ob-
served one-year dosing patterns within a managed care population of psoriatic
arthritis (PsA) patients.METHODS: IMS LifeLink™Health Plan Claims databasewas
utilized to identify patients with: index golimumab claim (4/24/2009-01/06/2010);
age 18 years at index; 1 PsA diagnosis code (696.0); and 12/ 12 months pre-/
post-index continuous enrollment. Biologic experiencewas defined as1medical/
pharmacy claims for another biologic 12 months prior to the first golimumab pre-
scription. Golimumab utilization was reported as the proportion of patients and
prescriptions at the recommended 50 mg dose, and prescription intervals, for the
12 month post-index period. Annual costs were modeled using the golimumab
United States wholesale acquisition cost (effective 7/5/2011) of $1,941.65 per 50mg.
RESULTS: 127 PsA patients receiving golimumab (n914 prescriptions) were iden-
tified; 59.8% were female; meanSD age was 4910 years. The majority (78.7%) of
patients had pre-index biologic experience; 73.0% experienced 1 unique biologic,
24.0% experienced 2 unique biologics, and 3.0% experienced 3 unique biologics at
some time point before golimumab. A 50 mg golimumab dose was dispensed in
95.3% of all PsA patients upon initiation and 96.6% of all prescriptions. The dose at
each of the first 12 prescription fills was 50mg for 95.2%-97.9% of patients. A 50mg
dose was dispensed upon initiation in 94.0% and 100.0% of biologic-experienced
and non-biologic-experienced PsA patients, respectively. Overall meanSD inter-
val between prescriptions was 3214 days; median was 30 days. Based upon ob-
served prescription intervals, a mean annual acquisition cost of $22,135 would be
realized. CONCLUSIONS: The majority of PsA patients receiving golimumab was
biologic-experienced and received a 50mg dose on amonthly basis with no appar-
ent increased dose requirement. Estimated average annual per patient golimumab
cost in a managed care PsA population would be $22,135.
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OBJECTIVES: To describe the 2-year disease-related direct healthcare costs of pso-
riatic arthritis (PsA) patients, in managed care, prior to initiating golimumab
(baseline).METHODS: The IMS LifeLink™Health Plan Claims databasewas utilized
to identify patients who had/were: index golimumab pharmacy claim started April
24, 2009-June 30, 2010; aged18 years at index;1 PsA ICD-9 diagnosis code (696.0);
and 24 months pre- and  6 months post-index continuous enrollment. Total
disease-related direct healthcare costs included medical (inpatient, outpatient)
and pharmacy (biologic and non-biologic treatment) costs. Disease-related allow-
able healthcare costswere calculated fromoutpatient and inpatient claimswith an
ICD-9 diagnosis code for PsA (696.0) or rheumatoid arthritis (RA-714.xx). Pharmacy
costs were calculated from allowed costs for biologic and non-biologic treatments
used in PsA, RA, or psoriasis. RESULTS: A total of 211 golimumab patients with PsA
(n180 with pre-index biologic experience) were analyzed; meanSD age was
5010; 61.1% female. Concomitant diagnosis codes for RA or psoriasis were found
in 39.8% and 51.2% of all PsA patients, respectively. Total meanSD pre-index
PsA-related costs were $3,569$9,231. Mean PsA-related outpatient medical costs
represented 92.0% of total PsA-related costs. Among the 114 patients with a comor-
bid RA diagnosis code, overall mean pre-index total RA-related costs were $2186.
Mean disease-related pharmacy costs for the 2-year period prior to golimumab
totaled $28,041. Based on the disease-related outpatient, inpatient, and pharmacy
costs, the 2-year direct mean per patient disease-related health care costs in PsA
was $32,791. CONCLUSIONS: In this study, annual managed care per patient direct
PsA healthcare costs were $16,369. This new economic burden of illness estimate
may further aid decisionmakers in assessing the cost-effectiveness and budgetary
impact of PsA therapies, including biologics. This estimate, however, should be
considered in the context of incremental improvements in clinical outcomes asso-
ciated with biologic treatments compared with older PsA therapies.
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